English | 简体中文 | 繁體中文 | 한국어
 English Press Releases
 Pharma & Biotech Healthcare & Pharm
Olympus Opens New Global HQ for Therapeutic Solutions Division and U.S. Medical Business
Apr 08, 2021 10:00 HKT
Agilex Biolabs acquires leading biolab TetraQ for APAC Expansion Plans
Apr 07, 2021 15:00 HKT
Avantor Named Best Bioprocessing Supplier in Single-Use Manufacturing at Asia-Pacific Bioprocessing Excellence Awards 2021
Apr 06, 2021 13:29 HKT
China Medical System (0867.HK) Accelerating Development and Stepping to New Heights, Driven by Innovation
Apr 05, 2021 10:00 HKT
Universal Medical Announced its 2020 Annual Results
Mar 31, 2021 17:05 HKT
Azelis releases 'Action 2025', confirming sustainability as a key driver in growth strategy
Mar 31, 2021 11:00 HKT
Viva Biotech Announced 2020 Annual Results
Mar 31, 2021 07:05 HKT
China Medical System (0867) Ushers in a Revaluation with its Continuous Growth and Synergy between Innovative Business and New Businesses
Mar 30, 2021 20:35 HKT
TOT BIOPHARM Announces A Number of Key Anti-Tumor Drugs Have Entered the Pivotal Clinical Stage in 2020
Mar 24, 2021 07:35 HKT
TrialWire launches StudyBoost, the Clinical Trial Insurance Plan
Mar 24, 2021 05:00 HKT
Sino Biopharmaceutical 2020 Net Profit Grows to RMB2.77 Billion amid Adversity
Mar 23, 2021 17:09 HKT
Black Spade Capital Announces Acquisition of iRad Medical Holding
Mar 22, 2021 15:30 HKT
Agilex Biolabs Showcases Advanced Immunoassay and Immunobiology Services at Bio-Europe Spring 2021
Mar 22, 2021 08:00 HKT
Ocumension Therapeutics (1477.HK) Announces 2020 Annual Results
Mar 20, 2021 10:10 HKT
Jicheng Lyu: The Philanthropic Prophet
Mar 20, 2021 10:00 HKT
Milestone Development Achieved in Clinical Trials and Commercialization, Hua Medicine's Dorzagliatin Readying for NDA Submission
Mar 19, 2021 14:34 HKT
New INNCO Position Paper Outlines Why Bans on Popular Alternatives to Smoking Will Do More Harm Than Good
Mar 17, 2021 16:15 HKT
The third TDMall in the world opened in Sydney, Australia
Mar 16, 2021 19:52 HKT
Alvotech Completes Second Round of a US$100 Million Private Placement
Mar 15, 2021 17:38 HKT
Avance Clinical Client Atossa Therapeutics Announces Final Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19
Mar 12, 2021 11:00 HKT
Next >>
Copyright © 2021 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: